Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Total Current Liabilities (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Total Current Liabilities for 6 consecutive years, with $25.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 43.18% to $25.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.0 million through Dec 2025, up 43.18% year-over-year, with the annual reading at $25.0 million for FY2025, 43.18% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $25.0 million at Janux Therapeutics, down from $27.8 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $27.8 million in Q3 2025, with the low at $9.2 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $15.9 million, with a median of $16.1 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities skyrocketed 302.29% in 2021, then plummeted 35.52% in 2024.
  • Over 5 years, Total Current Liabilities stood at $12.8 million in 2021, then grew by 28.99% to $16.5 million in 2022, then fell by 21.05% to $13.0 million in 2023, then surged by 33.96% to $17.5 million in 2024, then surged by 43.18% to $25.0 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $25.0 million, $27.8 million, and $21.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.